Sign In
Buy PALI
$1.93
+0.0700 (+3.76%)
At Close: Jun 03, 2026
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
09:00am, Wednesday, 27'th May 2026
Management presentation to take place on Thursday, June 4 th at 3:45 PM ET Register for the webcast here Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
04:15pm, Tuesday, 12'th May 2026
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance she
Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
08:50am, Thursday, 16'th Apr 2026
Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-st
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Analysts
04:14am, Saturday, 11'th Apr 2026
Shares of Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports. On
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
09:00am, Wednesday, 08'th Apr 2026
Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the �
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease
04:01pm, Monday, 30'th Mar 2026
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating
10:46am, Monday, 23'rd Mar 2026
I initiate Palisade Bio with a speculative buy, citing its differentiated microbiome-activated PDE4 inhibitor, PALI-2108, targeting IBD. PALI-2108's phase 1 data show promising efficacy, mechanistic e
Palisade Bio, Inc. (NASDAQ:PALI) Receives $13.25 Average Price Target from Analysts
01:16am, Friday, 20'th Mar 2026
Shares of Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are currently covering the firm, Marketbeat reports. One
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
09:00am, Monday, 02'nd Mar 2026
Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-da
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days
Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest
03:31am, Thursday, 19'th Feb 2026
Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 21,095,322 shares, a growth
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
08:45am, Tuesday, 17'th Feb 2026
Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
09:00am, Monday, 09'th Feb 2026
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (�
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:45am, Thursday, 05'th Feb 2026
Virtual presentation scheduled for Thursday, February 26 th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or
